Links

Reduction in Viral Load in AIDS Patients with Intravenous Mild Silver Protein – Three Case Reports

Authors: Dr. Ward Dean, M.D., Pensacola, Florida
Dr. Glen Wilcoxson, M.D., Gulf Shores, Alabama

Abstract:
Mild Silver Protein (MSP) has been used since the 19th century as an antimicrobial agent, with a wide range of bactericidal, fungicidal and virucidal properties. This paper documents the effectiveness of intravenous MSP to cause a dramatic reduction in viral load of three HIV + patients.

Introduction:
Silver has historically been used to speed wound healing, treat infections, purify water and preserve beverages. The modern era of medical use of Silver began in 1893, when C. Von Nageli reported the first systematic investigation into the lethal effects of metals [especially silver] on bacteria and lower life forms.2
Silver was one of the mainstays of medical practice in Europe and America during the period from 1900 to the beginning of the modern antibiotic era, which began in the 1940s with the introduction of sulfa drugs and penicillin. Various forms of Silver were used to treat literally hundreds of ailments: lung infections such as pneumonia, tuberculosis and pleurisy;3 sexual diseases such as gonorrhea and syphilis;4 skin conditions such as cuts, wounds, leg ulcers, pustular eczema, impetigo and boils,4 acute meningitis and epidemic cerebra-spinal meningitis;3 infectious diseases such as Mediterranean fever, erysipelas, cystitis, typhus, typhoid fever, and tonsillitis;3 eye disorders such as dacryocystitis, corneal ulcers, conjunctivitis and blepharitis;5 and various forms of septicemia 3, 6 including puerperal fever, peritonitis and post-abortion septicemia.3 Silver is unique among antimicrobial agents in its broad spectrum of action. It has been claimed to kill some 650 different disease organisms.13
In 1939, Hill and Pillsbury listed 94 different proprietary Silver preparations in use up to that time and in the Merck manual up to 1970. However, with the development of the antibiotic era, Ag rapidly fell into disuse and the medical "memory hole." It was replaced first by sulfa drugs, then penicillin (post WWII), and since then by hundreds of specialized antibiotics.
Nevertheless, Mild Silver Protein and Strong Silver Protein were listed in the National Dispensatory until at least 1955. Mild silver protein has been claimed to kill some 650 different disease organisms.
In 1994, Bill McFarland, a Louisiana-based businessman was introduced to MSP by a physician friend. He began to use it personally for minor viral infections, and recommended it to friends for oral and topical use for a variety of clinical conditions. As he became convinced of its efficacy for both viral and bacterial infections, he speculated that it might have positive effects in ameliorating serious, difficult-to-treat infectious diseases-and that it might be even more effective when administered intravenously. He convinced a physician in Mexico to administer the infusions, and developed a preliminary experimental protocol in conjunction with the Mexican physician and Joe J. Cardot, N.D., a Colorado naturopathic physician, using an updated potentiated MSP product.

Materials and Methods:
In 1997, McFarland recruited three subjects with HIV to participate in clinical trials with potentiated MSP. The initial protocol involved progressively increasing amounts and concentrations of MSP administered orally for 30-60 days, followed by a series of intravenous infusions of MSP in concentrations ranging from 40PPM to 1,500 PPM. Medical records for the three subjects were obtained - to as great a degree as possible – from the subjects’ personal physicians, and from the NO AIDS Task Force at Charity Hospital in New Orleans, LA.
MSP was initially provided by Discovery Experimental of Tampa, Florida, which at that time manufactured McFarland’s silver, and later by his own company, Natrition, Inc. Subjects were started on oral MSP 400 PPM at standard dosages (several teaspoons daily in divided doses) for approximately one month prior to administering MSP intravenously. Oral MSP was continued throughout the test period.
One hundred twenty ml. MSP in concentrations of 40,400 and 1,500 PPM (2 SUBJECTS [AP and RC], one time each), in a carrier solution of 500 cc ½ normal saline –to which 10 cc DMSO was added (it was believed that DMSO would enhance the efficacy of MSP) – were infused over two-three hours. Physicians in Mexico and the US monitored the patients for twenty-four hours a day for 5-7 days after each IV infusion, and once a week thereafter, via office visits and almost daily telephone conversations.

Results:
The medical history and limited laboratory results of the three subjects in this study are outlined below.
AP. AP is a white male, born in 1967. Records from Charity Hospital reveal that he was diagnosed with HIV in February 1993. At that time, he weighed 137 pounds, and his only abnormal physical finding was swollen inguinal lymph nodes. In April 1995, AP was treated for nausea, vomiting, diarrhea, and shingles. In August 1996, he began to complain of anxiety, diarrhea, and weight loss, for which he began to seek more regular medical treatment. Although intermittent courses of antibiotics were prescribed for diarrhea, Zorvirax for shingles, and AZT for HIV, AP seldom completed a course of any of these medications.
At the time he entered the experimental trial with potentiated MSP in October of 1997, AP was on no other medication. He weighed 132lbs. And was unable to walk without assistance due to fatigue and weakness. His viral load was over 750,000 – the maximum detectable limit of the instrument.
AP’s first IV infusion was in December of 1997. Therapies administered in this program are outlined in Table I. Thirty days and five MSP infusions later; AP’s viral load was 39,000. One month later, with no additional infusions, the viral load was down to 400 (Table I) (Fig. 1). AP Viral Load
RC. RC is a Puerto Rican male, born in 1950. He does not smoke cigarettes, drinks alcohol moderately, and eats a healthy diet. He does smoke marijuana. RC’s male roommate died of AIDS/HIV at Charity Hospital in 1986 at the age of 30. RC’s medical history includes Hepatitis A and B. RC has been a waiter most of his adult life, and also worked as a carpenter with his father on weekends, renovating houses.In 1987, RC enrolled in Charity Hospital’s "No Aids Task Force" where he tested positive for HIV. No viral load or T cell count data are available. RC believed he had only two years to live. For the next ten years, he kept waiting to die – but did not. In the summer of 1997, he began to note a decrease in energy, and increased requirement for sleep, causing him to discontinue his work as a carpenter. He volunteered for the experimental MSP treatment program in November 1997.
RC received five IV infusions on the same date and same dosage as AP (Table I). He received an additional 400-PPM infusion on 27 February. He continued on oral MSP 400 until June of 1998, when he discontinued participation in the program. RC noted a dramatic restoration of his energy levels, and returned to his former occupation as a waiter, and usually worked up to two shifts a day from 12:00 noon until 12:00 or 1:00 in the morning. RC Viral Load
Because of his restored energy levels, RC no longer felt a need to visit McFarland’s office. Although RC would not return to the office, McFarland went to his place of employment with a physician friend every weekend in March and April. RC promised to obtain additional records form the State of Louisiana, but he unfortunately never followed through.
RM is a white female, born in 1976, who was diagnosed HIV + in October 1997. When she first presented, she not only had full-blown AIDS, but also suffered for severe furunculosis and vaginal candidiasis. She took oral MSP for forty-five days before she received her first IV infusion. All of her other conditions were resolved with oral MSP therapy. A herxheimer-like reaction began about 2 ½ hours after beginning the infusion. The reaction was manifested by headaches, myalgias, and inability to sleep, and lasted for about 8 hours. By 10:00 a.m. The next morning, she felt fine and ate a large breakfast.
GH. GH is a white male (DOB 1948), who has been HIV + SINCE 1985. GH began taking MSP 400 PPM 1 tsp. TID on 4 April 1998. His HIV – 1 RNA (viral load) test on 9 June 1998 was 13,752 copies/ml. On 10 June 1998 he was given an infusion of MSP 400 PPM. He continued oral MSP through the end of July 1998. On July 20, a second HIV – 1 RNA test was performed, which revealed a dramatic drop of viral load to 2,215 copies/ml (Fig. 3). Lab Values for GH
Adverse effects noted by all subjects to a greater or lesser degree were (Jarish) Herxheimer-like reactions, lasting from 2-8 hours. These reactions, which usually started from 1-4 hours after the conclusion of the infusion included nausea, vomiting, fever, myalgias, and headache. The reaction appeared to decrease with repeated infusions. Whether this reaction was a true Herxheimer reaction or an inflammatory effect of the silver has not been conclusively determined. However, any damage appears to be self-limiting and rapidly reversible, as demonstrated by AP’s rapid rebound in hematological status, despite an intervening 400-PPM infusion.

Discussion:
McFarland regrets the admittedly fragmentary data. There are several reasons for this. McFarland, as stated previously, was a businessman. He had no scientific or medical training other than that which he obtained as an avid reader of medical books and what he gleaned from discussions with his physician and scientist friends. He was absolutely convinced of the efficacy of mild silver protein as a broad-spectrum anti-infective agent, based on his personal experience and those of his friends. He was positive it would be efficacious as well on many difficult to treat or even "non-treatable" illnesses. He believed that if he could demonstrate its safety and efficacy on a few severely ill patients, many sick people and their physicians would rapidly avail themselves of this innovative and relatively inexpensive therapy.
A large part of his confidence was based on individual research after MSP’s manufacture by Bayer & Company and Merck and Company had ended. MSP was also dropped from the USP and (34, 35, 36, 37,) NF Formularies shortly before 1970. This later research has shown potentiators and carriers to be paramount in MSP’s anti-infective success. Particle size, which is a main determinant of efficacy, is now controlled by these potentiators.
To prove his case, he chose among the most difficult conditions there are—AIDS, Lyme Disease, and Hepatitis C. He advertised for experimental subjects who suffered from these conditions. McFarland set up the protocol himself, after consulting with physicians in Mexico, Cuba, and the U.S. However, the physicians only made recommendations to him. McFarland had the final say. No physician was "in-charge," although McFarland hired physicians to perform all medically related procedures.
All patient information and laboratory data are derived from patient records and laboratory reports. Unfortunately, once the patient’s physicians found out about the "experiments in Mexico" McFarland’s ability to obtain follow-up medical records diminished dramatically. Despite records release forms from each subject, and intervention by attorneys, the local physicians and the state of Louisiana largely refused to cooperate.
Also, McFarland learned belatedly that his subjects were less than responsible, and were not interested in continuing treatment beyond the point that they felt well enough to return to their former destructive lifestyles. Consequently, they were erratic in following through with their treatments, and did not greatly assist him in obtaining follow-up records. In retrospect, he realizes he should have arranged for the study to be conducted by a physician, under more controlled conditions, so that complete records could have been maintained. McFarland relied on the federally funded "No Aids Project" (in which all of the subjects had been enrolled) for two reasons. First, as economy measure, since he had funded the entire trial out of his own pocket. This included round-trip tickets to Mexico, room, board, medical tests and health care for the patients. The other reason was to lend credibility to his study. He believed that the quasi-official and totally non-biased medical records maintained by the "No Aids Project" would lend credibility to his study. However, this plan turned out to be disappointing, as the physicians and administrators of the No Aids Program became a major stumbling block in their repeated refusal to release records of these patients.
All three subjects experienced a dramatic reversal in what had been their rapidly deteriorating clinical condition. This change was so dramatic, in fact, that all felt well enough to return to their former lifestyles. Unfortunately, they did not maintain the lifestyle changes recommended by their physicians, and two (AP and GH) moved out of town. RC is actively employed, but declines further treatment, as he does not feel ill. The last McFarland heard from AP and GH was that they also did not feel ill, and saw no need to continue his treatments. As far as we know, all three are still alive, and two (RC and GH) are actively employed.
Nevertheless, as fragmentary and incomplete as these data and records are, we believe the results are so dramatic that they deserve publication. The dramatic reduction in viral load in these three subjects is certainly no coincidence, and cannot be ignored.
We wish to see long-term follow-up, and to see how low and for how long the viral load could be reduced, and to monitor changes in CD4/CD8 ratios. However, such changes take more time than these patients were willing to give in continuing their treatments.
As flawed as this study is, we believe McFarland has accomplished several things. First, he demonstrated the apparent safety of intravenous MSP at a concentration of 400 PPM, confirming many of the studies from the 20’s, 30’s and 40’s. Second, he also demonstrated that high concentrations are probably toxic, as demonstrated by the dramatic drop in AP’s hematological status following the 1,500-PPM infusion. Third, and most important, he demonstrated the apparent ability of MSP to dramatically reduce the viral load and cause clinical reversals of rapidly deteriorating patients with HIV.
Early indications from McFarland’s work with Lyme Disease, Arthritis, Influenza and Hepatitis C (confirmed by our own preliminary experience) is that MSP appears to be effective in these conditions, as well. Results for these conditions will be published separately.

Conclusion:
Intravenous Mild Silver Protein 400ppm appears to be safe, effective virucidal agent in HIV + patients. Although the optimum dosage, frequency and half-life of infusions have not been determined, it appears that one or two infusions weekly appear to be a safe and effective regimen. We believe the frequency should be adjusted downward based on the presence and severity of Herxheimer-like reactions. The use of MSP in other conditions is currently being evaluated.

References and Publications of Interest:
Thompson, N.R. Comprehensive Inorganic Chemistry, Vol. 5 ch. 28, Elmsford, N.Y.: Perganton Press, 1973.
Duhamel, B. Electric Metal Colloids and Their Therapeutical Applications Lancet, 1912, Jan. 13
Searle, A. The Use of Colloids in Health and Disease, London: Constable & Co, 1920 pp 67-111.
Legge Roe, A. Collosol Argentum and its Optalmic Uses, Br. Med Jan 1916, Jan-June, 136-141.
Van Amber Brown, G. Colloidal Silver in Sepsis. Am J. Obstetrics, 1916, Jan-June, 136-141.
Hill, W and Pillsbury, D Argyria- The Pharmacology of Silver, Baltimore: Williams & Wilkins, 1939.
Romans, I Silver Compounds and Oligodynamic Metals in Antiseptics, Disinfectants. Fungicides and Chemical and Physical Sterilization, 1954, G. Reddish, ed., Philadelphia: Lea & Febiger, 380-428.
Committee on National Formulary, The National Formulary, Tenth Edition, American Pharmaceutical Association, Washington, D.C., 1955.
Anonymous, Argonin, Protorgol, Merck’s Manual, Merck and Company, New York, 1899. pp. 19, 59.
Fantus, Dinkelspiel et al, Merck Manual (Materia Medica), Rahway New Jersey, 1940, p. 1387
Taber’s Cyclopeidic Medical Dictionary, 1940, p A-91, s-48, s-63, 1940 (title page missing)
Ackerman, L., Baron, F et al. Blakiston’s New Gould Medical Dictionary, Blackiston Company, Maple Press, York, Pennsylvania, 1949, p. 934
Stecher, Finkel et al, Merck & Company., Rahway N.J. Mild Silver Protein, Merck Index, 1960, p. 686.

DISCLAIMER
The uses and protocols noted herein have been reported by practicing physicians. We make NO claims that these products cure, mitigate, alleviate, or prevent any specific disease, affliction, or conditions, including those reported here



	Reduction in Viral Load in AIDS Patients with Intravenous Mild Silver Protein – Three Case Reports Authors: Dr. Ward Dean, M.D., Pensacola, Florida Dr. Glen Wilcoxson, M.D., Gulf Shores, Alabama Abstract: Mild Silver Protein (MSP) has been used since the 19th century as an antimicrobial agent, with a wide range of bactericidal, fungicidal and virucidal properties. This paper documents the effectiveness of intravenous MSP to cause a dramatic reduction in viral load of three HIV + patients. Introduction: Silver has historically been used to speed wound healing, treat infections, purify water and preserve beverages. The modern era of medical use of Silver began in 1893, when C. Von Nageli reported the first systematic investigation into the lethal effects of metals [especially silver] on bacteria and lower life forms.2 Silver was one of the mainstays of medical practice in Europe and America during the period from 1900 to the beginning of the modern antibiotic era, which began in the 1940s with the introduction of sulfa drugs and penicillin. Various forms of Silver were used to treat literally hundreds of ailments: lung infections such as pneumonia, tuberculosis and pleurisy;3 sexual diseases such as gonorrhea and syphilis;4 skin conditions such as cuts, wounds, leg ulcers, pustular eczema, impetigo and boils,4 acute meningitis and epidemic cerebra-spinal meningitis;3 infectious diseases such as Mediterranean fever, erysipelas, cystitis, typhus, typhoid fever, and tonsillitis;3 eye disorders such as dacryocystitis, corneal ulcers, conjunctivitis and blepharitis;5 and various forms of septicemia 3, 6 including puerperal fever, peritonitis and post-abortion septicemia.3 Silver is unique among antimicrobial agents in its broad spectrum of action. It has been claimed to kill some 650 different disease organisms.13 In 1939, Hill and Pillsbury listed 94 different proprietary Silver preparations in use up to that time and in the Merck manual up to 1970. However, with the development of the antibiotic era, Ag rapidly fell into disuse and the medical "memory hole." It was replaced first by sulfa drugs, then penicillin (post WWII), and since then by hundreds of specialized antibiotics. Nevertheless, Mild Silver Protein and Strong Silver Protein were listed in the National Dispensatory until at least 1955. Mild silver protein has been claimed to kill some 650 different disease organisms. In 1994, Bill McFarland, a Louisiana-based businessman was introduced to MSP by a physician friend. He began to use it personally for minor viral infections, and recommended it to friends for oral and topical use for a variety of clinical conditions. As he became convinced of its efficacy for both viral and bacterial infections, he speculated that it might have positive effects in ameliorating serious, difficult-to-treat infectious diseases-and that it might be even more effective when administered intravenously. He convinced a physician in Mexico to administer the infusions, and developed a preliminary experimental protocol in conjunction with the Mexican physician and Joe J. Cardot, N.D., a Colorado naturopathic physician, using an updated potentiated MSP product. Materials and Methods: In 1997, McFarland recruited three subjects with HIV to participate in clinical trials with potentiated MSP. The initial protocol involved progressively increasing amounts and concentrations of MSP administered orally for 30-60 days, followed by a series of intravenous infusions of MSP in concentrations ranging from 40PPM to 1,500 PPM. Medical records for the three subjects were obtained - to as great a degree as possible – from the subjects’ personal physicians, and from the NO AIDS Task Force at Charity Hospital in New Orleans, LA. MSP was initially provided by Discovery Experimental of Tampa, Florida, which at that time manufactured McFarland’s silver, and later by his own company, Natrition, Inc. Subjects were started on oral MSP 400 PPM at standard dosages (several teaspoons daily in divided doses) for approximately one month prior to administering MSP intravenously. Oral MSP was continued throughout the test period. One hundred twenty ml. MSP in concentrations of 40,400 and 1,500 PPM (2 SUBJECTS [AP and RC], one time each), in a carrier solution of 500 cc ½ normal saline –to which 10 cc DMSO was added (it was believed that DMSO would enhance the efficacy of MSP) – were infused over two-three hours. Physicians in Mexico and the US monitored the patients for twenty-four hours a day for 5-7 days after each IV infusion, and once a week thereafter, via office visits and almost daily telephone conversations. Results: The medical history and limited laboratory results of the three subjects in this study are outlined below. AP. AP is a white male, born in 1967. Records from Charity Hospital reveal that he was diagnosed with HIV in February 1993. At that time, he weighed 137 pounds, and his only abnormal physical finding was swollen inguinal lymph nodes. In April 1995, AP was treated for nausea, vomiting, diarrhea, and shingles. In August 1996, he began to complain of anxiety, diarrhea, and weight loss, for which he began to seek more regular medical treatment. Although intermittent courses of antibiotics were prescribed for diarrhea, Zorvirax for shingles, and AZT for HIV, AP seldom completed a course of any of these medications. At the time he entered the experimental trial with potentiated MSP in October of 1997, AP was on no other medication. He weighed 132lbs. And was unable to walk without assistance due to fatigue and weakness. His viral load was over 750,000 – the maximum detectable limit of the instrument. AP’s first IV infusion was in December of 1997. Therapies administered in this program are outlined in Table I. Thirty days and five MSP infusions later; AP’s viral load was 39,000. One month later, with no additional infusions, the viral load was down to 400 (Table I) (Fig. 1). AP Viral Load RC. RC is a Puerto Rican male, born in 1950. He does not smoke cigarettes, drinks alcohol moderately, and eats a healthy diet. He does smoke marijuana. RC’s male roommate died of AIDS/HIV at Charity Hospital in 1986 at the age of 30. RC’s medical history includes Hepatitis A and B. RC has been a waiter most of his adult life, and also worked as a carpenter with his father on weekends, renovating houses.In 1987, RC enrolled in Charity Hospital’s "No Aids Task Force" where he tested positive for HIV. No viral load or T cell count data are available. RC believed he had only two years to live. For the next ten years, he kept waiting to die – but did not. In the summer of 1997, he began to note a decrease in energy, and increased requirement for sleep, causing him to discontinue his work as a carpenter. He volunteered for the experimental MSP treatment program in November 1997. RC received five IV infusions on the same date and same dosage as AP (Table I). He received an additional 400-PPM infusion on 27 February. He continued on oral MSP 400 until June of 1998, when he discontinued participation in the program. RC noted a dramatic restoration of his energy levels, and returned to his former occupation as a waiter, and usually worked up to two shifts a day from 12:00 noon until 12:00 or 1:00 in the morning. RC Viral Load Because of his restored energy levels, RC no longer felt a need to visit McFarland’s office. Although RC would not return to the office, McFarland went to his place of employment with a physician friend every weekend in March and April. RC promised to obtain additional records form the State of Louisiana, but he unfortunately never followed through. RM is a white female, born in 1976, who was diagnosed HIV + in October 1997. When she first presented, she not only had full-blown AIDS, but also suffered for severe furunculosis and vaginal candidiasis. She took oral MSP for forty-five days before she received her first IV infusion. All of her other conditions were resolved with oral MSP therapy. A herxheimer-like reaction began about 2 ½ hours after beginning the infusion. The reaction was manifested by headaches, myalgias, and inability to sleep, and lasted for about 8 hours. By 10:00 a.m. The next morning, she felt fine and ate a large breakfast. GH. GH is a white male (DOB 1948), who has been HIV + SINCE 1985. GH began taking MSP 400 PPM 1 tsp. TID on 4 April 1998. His HIV – 1 RNA (viral load) test on 9 June 1998 was 13,752 copies/ml. On 10 June 1998 he was given an infusion of MSP 400 PPM. He continued oral MSP through the end of July 1998. On July 20, a second HIV – 1 RNA test was performed, which revealed a dramatic drop of viral load to 2,215 copies/ml (Fig. 3). Lab Values for GH Adverse effects noted by all subjects to a greater or lesser degree were (Jarish) Herxheimer-like reactions, lasting from 2-8 hours. These reactions, which usually started from 1-4 hours after the conclusion of the infusion included nausea, vomiting, fever, myalgias, and headache. The reaction appeared to decrease with repeated infusions. Whether this reaction was a true Herxheimer reaction or an inflammatory effect of the silver has not been conclusively determined. However, any damage appears to be self-limiting and rapidly reversible, as demonstrated by AP’s rapid rebound in hematological status, despite an intervening 400-PPM infusion. Discussion: McFarland regrets the admittedly fragmentary data. There are several reasons for this. McFarland, as stated previously, was a businessman. He had no scientific or medical training other than that which he obtained as an avid reader of medical books and what he gleaned from discussions with his physician and scientist friends. He was absolutely convinced of the efficacy of mild silver protein as a broad-spectrum anti-infective agent, based on his personal experience and those of his friends. He was positive it would be efficacious as well on many difficult to treat or even "non-treatable" illnesses. He believed that if he could demonstrate its safety and efficacy on a few severely ill patients, many sick people and their physicians would rapidly avail themselves of this innovative and relatively inexpensive therapy. A large part of his confidence was based on individual research after MSP’s manufacture by Bayer & Company and Merck and Company had ended. MSP was also dropped from the USP and (34, 35, 36, 37,) NF Formularies shortly before 1970. This later research has shown potentiators and carriers to be paramount in MSP’s anti-infective success. Particle size, which is a main determinant of efficacy, is now controlled by these potentiators. To prove his case, he chose among the most difficult conditions there are—AIDS, Lyme Disease, and Hepatitis C. He advertised for experimental subjects who suffered from these conditions. McFarland set up the protocol himself, after consulting with physicians in Mexico, Cuba, and the U.S. However, the physicians only made recommendations to him. McFarland had the final say. No physician was "in-charge," although McFarland hired physicians to perform all medically related procedures. All patient information and laboratory data are derived from patient records and laboratory reports. Unfortunately, once the patient’s physicians found out about the "experiments in Mexico" McFarland’s ability to obtain follow-up medical records diminished dramatically. Despite records release forms from each subject, and intervention by attorneys, the local physicians and the state of Louisiana largely refused to cooperate. Also, McFarland learned belatedly that his subjects were less than responsible, and were not interested in continuing treatment beyond the point that they felt well enough to return to their former destructive lifestyles. Consequently, they were erratic in following through with their treatments, and did not greatly assist him in obtaining follow-up records. In retrospect, he realizes he should have arranged for the study to be conducted by a physician, under more controlled conditions, so that complete records could have been maintained. McFarland relied on the federally funded "No Aids Project" (in which all of the subjects had been enrolled) for two reasons. First, as economy measure, since he had funded the entire trial out of his own pocket. This included round-trip tickets to Mexico, room, board, medical tests and health care for the patients. The other reason was to lend credibility to his study. He believed that the quasi-official and totally non-biased medical records maintained by the "No Aids Project" would lend credibility to his study. However, this plan turned out to be disappointing, as the physicians and administrators of the No Aids Program became a major stumbling block in their repeated refusal to release records of these patients. All three subjects experienced a dramatic reversal in what had been their rapidly deteriorating clinical condition. This change was so dramatic, in fact, that all felt well enough to return to their former lifestyles. Unfortunately, they did not maintain the lifestyle changes recommended by their physicians, and two (AP and GH) moved out of town. RC is actively employed, but declines further treatment, as he does not feel ill. The last McFarland heard from AP and GH was that they also did not feel ill, and saw no need to continue his treatments. As far as we know, all three are still alive, and two (RC and GH) are actively employed. Nevertheless, as fragmentary and incomplete as these data and records are, we believe the results are so dramatic that they deserve publication. The dramatic reduction in viral load in these three subjects is certainly no coincidence, and cannot be ignored. We wish to see long-term follow-up, and to see how low and for how long the viral load could be reduced, and to monitor changes in CD4/CD8 ratios. However, such changes take more time than these patients were willing to give in continuing their treatments. As flawed as this study is, we believe McFarland has accomplished several things. First, he demonstrated the apparent safety of intravenous MSP at a concentration of 400 PPM, confirming many of the studies from the 20’s, 30’s and 40’s. Second, he also demonstrated that high concentrations are probably toxic, as demonstrated by the dramatic drop in AP’s hematological status following the 1,500-PPM infusion. Third, and most important, he demonstrated the apparent ability of MSP to dramatically reduce the viral load and cause clinical reversals of rapidly deteriorating patients with HIV. Early indications from McFarland’s work with Lyme Disease, Arthritis, Influenza and Hepatitis C (confirmed by our own preliminary experience) is that MSP appears to be effective in these conditions, as well. Results for these conditions will be published separately. Conclusion: Intravenous Mild Silver Protein 400ppm appears to be safe, effective virucidal agent in HIV + patients. Although the optimum dosage, frequency and half-life of infusions have not been determined, it appears that one or two infusions weekly appear to be a safe and effective regimen. We believe the frequency should be adjusted downward based on the presence and severity of Herxheimer-like reactions. The use of MSP in other conditions is currently being evaluated. References and Publications of Interest: Thompson, N.R. Comprehensive Inorganic Chemistry, Vol. 5 ch. 28, Elmsford, N.Y.: Perganton Press, 1973. Duhamel, B. Electric Metal Colloids and Their Therapeutical Applications Lancet, 1912, Jan. 13 Searle, A. The Use of Colloids in Health and Disease, London: Constable & Co, 1920 pp 67-111. Legge Roe, A. Collosol Argentum and its Optalmic Uses, Br. Med Jan 1916, Jan-June, 136-141. Van Amber Brown, G. Colloidal Silver in Sepsis. Am J. Obstetrics, 1916, Jan-June, 136-141. Hill, W and Pillsbury, D Argyria- The Pharmacology of Silver, Baltimore: Williams & Wilkins, 1939. Romans, I Silver Compounds and Oligodynamic Metals in Antiseptics, Disinfectants. Fungicides and Chemical and Physical Sterilization, 1954, G. Reddish, ed., Philadelphia: Lea & Febiger, 380-428. Committee on National Formulary, The National Formulary, Tenth Edition, American Pharmaceutical Association, Washington, D.C., 1955. Anonymous, Argonin, Protorgol, Merck’s Manual, Merck and Company, New York, 1899. pp. 19, 59. Fantus, Dinkelspiel et al, Merck Manual (Materia Medica), Rahway New Jersey, 1940, p. 1387 Taber’s Cyclopeidic Medical Dictionary, 1940, p A-91, s-48, s-63, 1940 (title page missing) Ackerman, L., Baron, F et al. Blakiston’s New Gould Medical Dictionary, Blackiston Company, Maple Press, York, Pennsylvania, 1949, p. 934 Stecher, Finkel et al, Merck & Company., Rahway N.J. Mild Silver Protein, Merck Index, 1960, p. 686. DISCLAIMER The uses and protocols noted herein have been reported by practicing physicians. We make NO claims that these products cure, mitigate, alleviate, or prevent any specific disease, affliction, or conditions, including those reported here
	Site Map I Contact Us I Terms & Conditions